Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Yonesaka, Kimio, Haratani, Koji, Takamura, Shiki, Sakai, Hitomi, Kato, Ryoji, Takegawa, Naoki, Takahama, Takayuki, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Kato, Sigeki, Maenishi, Osamu, Sakai, Kazuko, Chiba, Yasutaka, Okabe, Takafumi, Kudo, Keita, Hasegawa, Yoshikazu, Kaneda, Hiroyasu, Yamato, Michiko, Hirotani, Kenji, Miyazawa, Masaaki, Nishio, Kazuto, Nakagawa, Kazuhiko·2018·Clinical Cancer Research

Abstract

Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed in various malignancies. To our knowledge, this study is the first to evaluate B7-H3 expression in NSCLCs treated with anti-PD-1 therapy and the therapeutic potential of a combination of anti-PD-1 therapy and B7-H3 targeting. Experimental Design: B7-H3 expression was evaluated immunohistochemically in patients with NSCLC (n = 82), and its relationship with responsiveness to anti-PD-1 therapy and CD8+ tumor-infiltrating lymphocytes (TILs) was analyzed. The antitumor efficacy of dual anti-B7-H3 and anti-programmed death ligand-1 (PD-L1) antibody therapy was evaluated using a syngeneic murine cancer model. T-cell numbers and functions were analyzed by flow cytometry. Results: B7-H3 expression was evident in 74% of NSCLCs and was correlated critically with nonresponsiveness to anti-PD-1 immunotherapy. A small number of CD8+ TILs was observed as a subpopulation with PD-L1 tumor proportion score less than 50%, whereas CD8+ TILs were still abundant in tumors not expressing B7-H3. Anti-B7-H3 blockade showed antitumor efficacy accompanied with an increased number of CD8+ TILs and recovery of effector function. CD8+ T-cell depletion negated antitumor efficacy induced by B7-H3 blockade, indicating that improved antitumor immunity is mediated by CD8+ T cells. Compared with a single blocking antibody, dual blockade of B7-H3 and PD-L1 enhanced the antitumor reaction. Conclusions: B7-H3 expressed on tumor cells potentially circumvents CD8+-T-cell–mediated immune surveillance. Anti-B7-H3 immunotherapy combined with anti-PD-1/PD-L1 antibody therapy is a promising approach for B7-H3–expressing NSCLCs. Clin Cancer Res; 24(11); 2653–64. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2852

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 167

Metadata

Authors
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., Kato, S., Maenishi, O., Sakai, K., Chiba, Y., Okabe, T., Kudo, K., Hasegawa, Y., Kaneda, H., Yamato, M., Hirotani, K., Miyazawa, M., Nishio, K., & Nakagawa, K.
Venue
Clinical Cancer Research
Published
2018-05-31
Volume
24
Issue
11
Pages
2653-2664
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2789620675
Cited by
167
References
20
FWCI
4.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-2852
The paper
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., Kato, S., Maenishi, O., Sakai, K., Chiba, Y., Okabe, T., Kudo, K., Hasegawa, Y., Kaneda, H., Yamato, M., . . . Nakagawa, K. (2018). B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-2852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.